Other languages Medivir AB

Equities

MVIR B

SE0020181014

Market Closed - Nasdaq Stockholm Other stock markets 08:59:50 29/04/2024 pm IST			5-day change	1st Jan Change
3.18 ^SEK	-1.85%		+11.58%	+11.58%

25/04	Medivir Gets Two US FDA Designations for MIV-711	MT
21/03	Certain Shares of Medivir AB are subject to a Lock-Up Agreement Ending on 21-MAR-2024.	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Medivir Presents Data That Strengthens the Fostrox/Lenvima Combination in Primary Liver Cancer At Easl Liver Cancer Summit	22/02
Medivir AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	15/02
Medivir AB Reports Earnings Results for the Full Year Ended December 31, 2023	15/02
Medivir Presents the First Clinical Data with Fostrox + Lenvima At the Asco GI Scientific Congress	18/01
Medivir AB Announces Further Improved Clinical Benefit with Fostrox + Lenvima as Data from the Ongoing Phase 1B/2A Study in Advanced Hepatocellular Cancer	17/01
Medivir AB Announces Data from Ongoing Phase 1B/2A Study in Advanced Hepatocellular Cancers	19/12
Medivir AB Agrees with Lonza to Manufacture a Fostrox GMP Campaign, to Be Tested in 2L HCC with Intent to Commercialize Via Accelerated Approval	13/12
Medivir AB Announces Updated Formulation of Fostrox Critical to Support Planned Study with Accelerated Approval Intent in Second Line HCC	27/11
Medivir AB to Present Clinical Data at ASCO-GI with Fostrox + Lenvima in HCC and Shares Positive Response from Type D Meeting with FDA	13/11
Medivir AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	27/23/27
Medivir AB to Report New and Updated Data from Ongoing Phase 2a HCC Study as Part of Its Third Quarter Report on Friday	25/23/25
Medivir AB Appoints Nomination Committee	23/23/23
Medivir AB Announces Resignation of Anette Lindqvist as Director	20/23/20
Medivir AB Announces All Patients in the Ongoing Phase 2A Study in Advanced Hepatocellular Car Car Car Carcinoma Has Now Dosed At Least Two Treatment Cycle	05/23/05
Medivir AB Reports Promising Interim Data, Including A First Complete Response in Phase 1B/2A Hcc Study with Fostrox in Combination with Lenvima	04/23/04
Medivir AB Announces Formation of A Scientific Advisory Council	07/23/07
Medivir AB Announces Patent Application for Fostrox Approval in China	19/23/19
Medivir AB Completes the Dose Escalation Part (Phase 1B) of the 1B/2A Study in Hcc and Focus on the Combination of Fostrox and Lenvima	02/23/02
Medivir AB Reports Earnings Results for the First Quarter Ended March 31, 2023	27/23/27
Medivir Presents New Data At AACR Showing Significantly Improved Antitumor Efficacy in Non Clinical Tumor Models with fostrox in Triple Combination	17/23/17

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Medivir AB

Equities

MVIR B

SE0020181014

Other languages

Filters